Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H15N3O |
Molecular Weight | 217.267 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1NC2=CC=CC=C2N1C3CCNCC3
InChI
InChIKey=BYNBAMHAURJNTR-UHFFFAOYSA-N
InChI=1S/C12H15N3O/c16-12-14-10-3-1-2-4-11(10)15(12)9-5-7-13-8-6-9/h1-4,9,13H,5-8H2,(H,14,16)
Molecular Formula | C12H15N3O |
Molecular Weight | 217.267 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/25131537Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28218826
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25131537
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28218826
4-(2-Keto-1-benzimidazolinyl)piperidine is building block for preparing potent anticancer compounds.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
In vitro inhibition of pimozide N-dealkylation by selective serotonin reuptake inhibitors and azithromycin. | 2002 Apr |
|
SAR studies of 6-aryl-1,3-dihydrobenzimidazol-2-ones as progesterone receptor antagonists. | 2005 Aug 1 |
|
Discovery and SAR studies of a novel series of noncovalent cathepsin S inhibitors. | 2005 Mar 15 |
|
The SAR of 4-substituted (6,6-bicyclic) piperidine cathepsin S inhibitors. | 2006 Apr 15 |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25131537
Compound (3, 4-(2-Keto-1-benzimidazolinyl)piperidine) activity was evaluated by annexin V/propidium iodide staining-based flow cytometric analysis in human K562 cells after 48h of treatment.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:23:54 GMT 2023
by
admin
on
Sat Dec 16 08:23:54 GMT 2023
|
Record UNII |
4RP0AED2PC
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
4RP0AED2PC
Created by
admin on Sat Dec 16 08:23:54 GMT 2023 , Edited by admin on Sat Dec 16 08:23:54 GMT 2023
|
PRIMARY | |||
|
20662-53-7
Created by
admin on Sat Dec 16 08:23:54 GMT 2023 , Edited by admin on Sat Dec 16 08:23:54 GMT 2023
|
PRIMARY | |||
|
243-950-3
Created by
admin on Sat Dec 16 08:23:54 GMT 2023 , Edited by admin on Sat Dec 16 08:23:54 GMT 2023
|
PRIMARY | |||
|
DTXSID0057679
Created by
admin on Sat Dec 16 08:23:54 GMT 2023 , Edited by admin on Sat Dec 16 08:23:54 GMT 2023
|
PRIMARY | |||
|
88638
Created by
admin on Sat Dec 16 08:23:54 GMT 2023 , Edited by admin on Sat Dec 16 08:23:54 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE |
This metabolism is catalyzed mainly by the cytochrome P450 3A4 (CYP 3A4) enzymatic system and to a lesser extent, by cytochrome P450 1A2 (CYP 1A2) and cytochrome P450 2D6 (CYP 2D6)
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|